Give the high rate of advances in the field of clinical hematology, the IACH News initiative enables experts in the field and key opinion leaders share the most up to date information in a timely manner, and in a format that is, focused, engaging and easy to access.
Dr. Oluwole Olalekan- Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL
Dr. Bhagirathbhai Dholaria- Omisirge Allogeneic Cord Blood-Based Cell Therapy Approved to Reduce Risk of Infection Following Stem Cell Transplantation
Dr. Paula Rodríguez Otero- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Prof. Christoph Stein Thoeringer- Role of the Gut Microbiome in CAR-T cell Therapy
Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Prof. Florent Malard- The First microbiota therapy approved by the US FDA
Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure
Prof. Mohamad Mohty – FDA Breakthrough Therapy Designation for Elranatamab in Relapsed or Refractory Multiple Myeloma
Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Prof. Mohamed Kharfan Dabaja – Positive Results from Final Progression-Free Survival Analysis of zanubrutinib Compared to ibrutinib in CLL
Dr. Areej El-Jawahri – Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma
Prof. He Huang – Non-viral, specifically targeted CAR-T cells, achieve high safety and efficacy in B-NHL
Prof. Mikkael Sekeres – Azacitidine plus venetoclax for myelodysplastic syndromes
Dr. Adi Nagler – Single cell sequencing to chronic lymphocytic leukemia
Prof. Meral Beksac – The recent developments in the field of bispecific T-cell engagers
Prof. Selim Corbacioglu – The importance of veno-occlusive disease prophylaxis
Prof. Paul Richardson – Melflufen for the treatement of relapsed-refractory myeloma
Prof. Mohamad Mohty – New treatments for refractrory acute GVHD
Dr. Eolia Brissot – Approval of maribvir for post-transplant cytomegalovirus infection
Prof. Sebastian Giebel – CAR T cells for adult ALL
Prof. Farhad Ravandi – MRD in AML
Prof. Iskra Pusic – Recent updated in Acute GVHD
Prof. Arnon Kater -State of the art therapy in CLL
Annalisa Ruggeri – Haplo versus matched unrelated transplant at the era of post-cyclophosphamide
Christopher Hourigan – How to distinguish to Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis?
Robert Zeiser – REACH3 trial results
Alex Lazaryan – Belumosudil’s FDA approval for cGVHD
Monzr Al Malki – The role of post cyclophosphamide, for GVHD prophylaxis, in the mismatched unrelated setting
Naveen Pemmaraju – Novel Therapeutic Approaches in BPDCN
Jurgen Kuball – Gammadelta T cells
Anna Sureda – Therapy of lymphomas, what’s new at EHA 2021
Nitin Jain – Therapy of CLL, what’s new at EHA 2021
Gram Jackson – Recently released paper on Improving prognostic assignment in older adults with MM
Mehdi Hamadani – Recently released ZUMA-7 trial results
Saad Usmani – Take-home messages, from ASCO, and EHA 2021
Luciano J. Costa – The role of auto in myeloma based on the ASCO 21 data
Jesus G. Berdeja – Results of the CARTITUDE-1 study
Arnon Nagler – Allo-transplant for AML: what’s new at EHA 2021
Mohamad Mohty – Advances in Multiple Myeloma as reported at EHA 2021
Ruben Mesa – Therapy of MPNs: what’s new at EHA 2021?
Dr. Jordan Gauthier – Results from Phase 3 TRANSFORM Trial
Dr. Jim Omel – The patient / cancer research advocate viewpoint from ASCO 2021
Prof. Mohamad Mohty – Multiple myeloma take home messages from ASCO 2021
